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LETTER TO THE EDITOR
Spontaneous Remission of Congenital Acute Myeloid Leukemia
With t(8;16)(p11;13)
To The Editor: We report a case of congenital acute myeloid
leukemia (AML) with t(8;16) that went into spontaneous
remission. A full-term female presented with blueberry muffin
spots at birth. A skin biopsy revealed a diffuse dermal infiltration
by immature hematopoietic cells and was diagnosed as myelo-
sarcoma (Fig. 1A and B). At Day 10, the patient’s bone marrow
showed 32.8% leukemic blasts (Fig. 1C and D). A subset of the
leukemic blasts was weakly positive for myeloperoxidase (MPO)
and others showed weak reactivity for nonspecific esterase (NSE)
(Fig. 1E and F), consistent with AML, M4 subtype by FAB criteria.
 2010 Wiley-Liss, Inc.
DOI 10.1002/pbc.22859
Published online in Wiley Online Library
(wileyonlinelibrary.com).
Fig. 1. Skin biopsy showed diffuse dermal infiltration by immature hematopoietic cells at low power (A, H&E 100X). The pleomorphic neoplastic
cells had larger irregular nuclei with prominent nucleoli and abundant basophilic cytoplasm (B, H&E 400X). Bone marrow was packed with these
neoplastic cells (D, bone marrow biopsy, H&E 400X). Wright stain showed large nuclei with prominent nucleoli, abundant cytoplasm, occasional
cytoplasmic vacuoles and fine esinophilic granules (C, bone marrow aspirate, Wright stain, 1000X), and dual postivities of MPO (E, cytochemic
stain 1000X), and NSE (F, cytochemic stain, 400X). Cytogenetics study showed t(8;16)(p11.2;p13.3) (G, arrow).
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Cytogenetic analysis showed 46, XX, t(8;16)(p11.2;p13.3)[20]
(Fig. 1G). The patient was managed conservatively with close moni-
toring of peripheral blood counts and serial studies of bone marrow,
lumbar puncture, and cytogenetics. The skin lesion regressed in
4 weeks. Four months after initial diagnosis, spontaneous remis-
sion was observed. The patient has remained in complete remission
for 11 months since initial diagnosis with normal cytogenetics.
Although leukemia is the most common malignancy in child-
hood, congenital AML with t(8;16)(p11.2;p13.3) is rare. Nine cases
including this case have been reported. These cases appear to have
distinct clinic manifestations. All patients presented with skin rash.
All but one leukemic patient was classified to have AML M4/M5,
with one diagnosed as malignant histiocytosis [1]. All five cases
reported after 1996 went into spontaneous remission [2–5], while
four cases reported before 1996 were treated with chemotherapy.
One possibility is that these treated cases might not have been given
enough time for spontaneous remission. If that is the case,
congenital AML with t(8;16) may be a self-limited disease.
The time to spontaneous remission ranged from 2 to 4 months
following initial diagnosis. All but one remain in complete
remission with or without chemotherapy during the time of follow
up, which varied from 2 weeks to 5 years. One reported death [6] was
due to pseudomonas infection after chemotherapy.
The t(8;16)(p11.2;p13.3) is characterized by fusion of MYST
histone acetyltransferase (monocytic leukemia) 3 (MYST3) on
chromosome 8p11 and CREB-binding protein (CREBBP) gene on
16p13. Breakpoints at different locations of MYST3 and CREBBP
generate seven fusion transcripts [2,7,8]. Type I (MYST3 exon 16-
CREBBP exon 3) is the most common form in adults with t(8;16)
AML and is associated with poor prognosis. Only two congenital
cases have been characterized by RT-PCR [2,3]. Wong et al. [2]
reported only reciprocal Type I (CREBBP exon 2-MYST3 exon 17);
while Terui et al. [3] reported Type VI (MYST3 exon 16-CREBBP
exon 7) and VII (MYST3 exon 16-CREBBP exon 8) that have never
been detected in adult patients.
In conclusion, although an identical translocation is observed in
both adult and congenital forms of t(8;16) positive leukemia, the
congenital form shows distinct clinicopathologic and prognostic
characteristics. Due to the possibility of spontaneous remission,
patients should be closely monitored with morphologic and
cytogenetic evaluation.
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